Outlook Therapeutics Stock (NASDAQ: OTLK)

Outlook Therapeutics Stock (NASDAQ:OTLK), Trade Ideas

Outlook Therapeutics

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Long Ideas

News

Small Cap

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

CION

OTLK

Although U.S. stocks closed mixed on Thursday, there were a few notable insider trades.

Insiders Buying Outlook Therapeutics And 2 Other Stocks

Earnings

Penny Stocks

Eurozone

Commodities

Global

Intraday Update

CUTR

ISPR

LULU

SINT

SMLP

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 0.3% on Friday.

The Dow traded down 0.49% to 39,585.67 while the NASDAQ rose 0.26% to 16,444.91. The S&amp;P 500 also rose, gaining, 0.01% to 5,241.56.

Gold Moves Lower; Lululemon Shares Plummet

Movers

ABTS

ALAB

AMTX

ANNX

ATER

BACK

BCAN

BIOL

BNAI

BTDR

CZOO

DNTH

EGOX

FRSX

GRDI

GRFS

GTBP

JOAN

LAAC

LICY

LXEH

MRNO

NKTX

NVFY

OCGN

RETO

SLNA

TROO

YTEN

Shares of  Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results.

Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics Inc

<p>As 4/20 is upons us, <a href="https://www.benzinga.com/topic/weedmaps">Weedmaps </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAPS#NASDAQ">MAPS</a>) has provided valuable insights to forecast a significant sales boost for the industry and a widespread celebration of marijuana. The data, derived from big data analysis of user activities on the platform, indicates that the previous year&#8217;s 4/20 was highly successful, with Weedmaps experiencing a twofold increase in normal operations.</p>
<h2 class="wp-block-heading">Big Data, Big Deals</h2>
<p>Weedmaps pointed out that consumers are prioritizing value, as the platform registered a 200% surge in orders that redeem deals through the platform during 4/20 week of 2023 compared to 2022.&nbsp;</p>
<p>Furthermore, the platform has observed a rising trend in usage, with deal claims increasing by 100% over 2022. This uptick is likely motivated by price reductions, as the costs for flowers, vape pens, and edibles have continued to decrease for the second consecutive year, showing declines of 15%, 14%, and 17% when compared to 2021.</p>
<p>Weemaps also shared that consumers will probably be expending even more in goods than years before, since the average order value surged to $96.22 in 2023, a 14% increase compared to an average Thursday in April of 2023. This is despite deflation.</p>
<p>Additionally, the quantity of orders expanded by an average of 25% in terms of items per basket on 4/20 of last year, in comparison to 2022.</p>
<h2 class="wp-block-heading">Category Insights</h2>
<ul>
<li>During the 4/20 retail week of 2023, vape pens witnessed a 29% growth over 2022, and an impressive 126% increase compared to 2020, with the largest demographic being Gen Z (31%).</li>
</ul>
<ul>
<li>Edibles are predominantly favored by consumers aged 50 and above, accounting for nearly half of all edible sales. The edibles category saw a 36% rise in orders during the 4/20 week of 2023 compared to the previous year.</li>
</ul>
<ul>
<li>Cannabis flower remains the top choice across all age groups, with nearly half of all orders on 4/20 in 2023 falling into this category. Remarkably, sales of flowers through Weedmaps surged by 47% on 4/20 compared to the prior year, and this growth expanded to 202% when compared to 4/20 in 2020.</li>
</ul>


Cannabis

MAPS

Unparalleled 4/20: Weedmaps Unveils Consumer Trends Ahead Of Cannabis Industry's Biggest Holiday

<p>As you may have heard, cannabis consumption among older folks is on the rise. More specifically, seniors are one of the fastest-growing groups of <a href="https://www.benzinga.com/cannabis">cannabis users in the U.S. </a></p>
<p>As it turns out, many older adults have been consuming weed for decades and new ones are joining in on the fun. Cannabis consumption among our parents and grandparents has quadrupled in the past eight years.</p>
<p>Study after study suggests that older adults are using cannabis to remedy an array of conditions such as sleep issues, pain,&nbsp;inflammation and to activate their appetites. </p>
<p>But most consume because they still enjoy getting high.</p>
<p>"Sure, I sleep better with cannabis and topical creams alleviate my knee pain, but that's all new. I've been smoking pot for the past four decades and I see no reason to stop getting high," said Cynthia P who recently retired as an ER nurse in Ohio where recreational marijuana <a href="https://www.benzinga.com/markets/cannabis/23/11/35664155/ohio-legalizes-cannabis-and-overwhelmingly-approves-abortion-rights">became legal</a> last November.</p>
<p>Scientists and researchers are wisely becoming interested in this Baby Boomer demographic of 77 million, many of whom are healthy, economically stable and have no plans of checking out anytime soon, so they say.</p>
<p>One particular<a href="https://www.frontiersin.org/articles/10.3389/fnagi.2022.804890/full" target="_blank" rel="noreferrer noopener">&nbsp;study</a>,&nbsp;that examined marijuana use in adults aged&nbsp;60 to 88 found that&nbsp;whole-plant cannabis did&nbsp;not harm&nbsp;cognition but rather the opposite.&nbsp;Older cannabis users, relative to non-users, had&nbsp;significantly greater neuronal communication between the cerebellum and hippocampus.</p>
<p><strong>Why?</strong> Age-related changes in the&nbsp;<a href="https://www.benzinga.com/markets/cannabis/22/07/28272841/the-endocannabinoid-system-101-the-basics-made-easy" target="_blank" rel="noreferrer noopener">endocannabinoid system</a>&nbsp;(ECS) include a decrease in the number of cannabinoid receptors throughout the brain.&nbsp;The ECS,&nbsp;a significant aspect of our human physiology that&nbsp;helps maintain homeostasis,&nbsp;is a complex cell-signaling system in the brain and body that interacts with just about all of our&nbsp;other body systems.&nbsp;</p>
<p><strong>Which means? </strong>During normal aging, the decline in cannabinoid receptors correlates with increased levels of inflammation in these brain regions causing a loss of neurons in the hippocampus, which is critical for learning and&nbsp;memory.&nbsp;This, in short, explains age-related memory impairment.&nbsp;&nbsp;</p>
<p>"Oh, I believe that," Cynthia told Benzinga. "While I never consumed for a full shift before going to work, I'm convinced that marijuana has helped keep me and my mind sharp as I aged. I'm not saying it's for everyone, but for people of my generation there's nothing better."</p>
<p><em>Now Read: <a href="https://www.benzinga.com/markets/cannabis/24/04/38341776/hemp-space-grew-3x-the-rate-of-cannabis-where-did-marijuana-get-it-wrong">Hemp Space Grew 3X The Rate Of Cannabis, Where Did Marijuana Get It Wrong?</a></em></p>
<p><em>Photo: Shutterstock</em></p>


Exclusives

It's 4/20, Do You Know Where Your Parents Are?

<p>The Detroit Lions finished with one of their best records in years for the 2023 season, which means they will have a lower pick in the<a href="https://www.benzinga.com/nfldraft/"> 2024 NFL Draft.</a></p>
<p>Would General Manager<strong> Brad Holmes</strong> consider trading out of the first round with the 2024 NFL Draft taking place in Detroit?</p>
<p><strong>What Happened: </strong>Detroit Lions fans might not like the answer given by Holmes to the media on scenarios that could see the Lions trade their 29<sup>th</sup> overall first-round pick and move back in the <a href="https://www.benzinga.com/nfldraft/detroit-live-events/">2024 NFL Draft.</a></p>
<p>Holmes was asked about a scenario of trading out of the first round and didn't hesitate to say he will do what is best for the franchise.</p>
<p>"We have to do the right thing for the organization," Holmes said, as <a href="https://www.detroitlions.com/news/holmes-prepared-to-apologize-to-fans-if-lions-trade-out-of-first-round">reported </a>by Lions writer Mike O'Hara.</p>
<p>Holmes said while he would consider trading out of the first round, it's important to note that, with the draft taking place in Detroit, there might be a greater chance of upsetting the fans if he makes such a move.</p>
<p>A trade out of the first round could mean that any Lions fans in attendance Thursday will have spent all day downtown to watch other teams take their players in the draft.</p>
<p>Holmes said he would send out a "PSA and apologize" if he trades out of the first round.</p>
<p>"Hopefully, our fans will forgive us. We won't expect immediate forgiveness right then and there, but hopefully when the season starts."</p>
<p>Detroit was announced as the host city for the NFL Draft back in 2022.</p>
<p>"Another opportunity for our franchise and our city and just for the world to kind of migrate to downtown Detroit," Holmes said earlier this week.</p>
<p><em>Related Link: <a href="https://www.benzinga.com/general/sports-betting/24/04/38318190/michigan-wolverines-will-have-6-high-demand-players-in-2024-nfl-draft-will-history-repeat-">Michigan Wolverines Will Have 6 High-Demand Players In 2024 NFL Draft: Will History Repeat Itself?</a></em></p>
<p><strong>Why It's Important:</strong> Holmes is no stranger to trading in the NFL Draft. Since joining as the Lions GM in 2021, Holmes has taken part in several drafts for the team and is known for dealmaking.</p>
<p>This includes the 2023 NFL Draft, which saw the Lions trade their sixth overall pick, acquired from the Los Angeles Rams in the <strong>Matthew Stafford</strong> trade. The Lions traded the sixth pick to the Arizona Cardinals and received back the 12<sup>th</sup>, 34<sup>th</sup> and 168<sup>th</sup> overall picks.</p>
<p>Lions fans will remember the 2023 Draft saw several impact players taken including running back <strong>Jahymyr Gibbs </strong>with the 12<sup>th</sup> pick and tight end<strong> Sam LaPorta </strong>with the 34<sup>th</sup> pick. Both rookies played in the 2023 NFL season and were among the top first-year players, finishing third and fourth, respectively, in NFC offensive rookie of the year voting.</p>
<p>The 12-5 record and appearance in the NFC Championship game gives the Lions the 29<sup>th</sup> overall pick, one of their lowest earned in years.</p>
<p>The Lions also have the 61<sup>st</sup> overall pick and 73<sup>rd</sup>, but have only those three picks in the first four rounds, with no fourth-round pick this year. This could prompt Holmes to be open to trades to pick up additional picks. The Lions also have a fifth-round pick, two sixth-round picks and a seventh-round pick, for seven overall picks.</p>
<p>In the 2023 NFL Draft, the Lions had eight picks, including two first-round picks and two second-round picks.</p>
<p>The Lions have had a first round pick in every season since 1994, with 1993 being the last year they didn't select a player in the first round.</p>
<p>The Lions&#8217; top needs by position include cornerback, offensive line and wide receiver. The Lions last took a wide receiver in the first round of 2022 (<strong>Jameson Williams</strong>) and a cornerback in the first round of 2020 (<strong>Jeff Okudah</strong>). For the offensive line, the Lions last took a guard or center in the first round in 2018 with <strong>Frank Ragnow,</strong> and last took an offensive tackle in the first round in 2021 with <strong>Penei Sewell.</strong> Of these four players, three are still with the Lions.</p>
<p>Join Benzinga's live draft reaction show Thursday, April 25 to hear our instant thought on who the Lions take 29<sup>th</sup> overall or our reaction to the Lions trading out of the first round.</p>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534; LIVE NFL Draft Watch Party: Benzinga&#039;s Expert Analysis &amp; Reactions!" width="500" height="281" src="https://www.youtube.com/embed/XMBqIWZb7h0?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p></p></figure></p>
<p><em>Photo via Shutterstock. </em></p>


Sports

Detroit Lions Have First-Round Pick Every Year Since 1994: Would They Really Trade Out With Draft In Motor City?

<p>&quot;We are disappointed to announce the wind-down of our Phase 2 NASH trial, which we attribute entirely to resource constraints,&quot; said John Brancaccio, Executive Chairman of Hepion. &quot;The Company remains committed to its strategic alternative efforts previously announced in December 2023. Given the number of enrolled NASH patients to date and the low probability of generating relevant efficacy data to support a registrational trial with our current cash resources, we have opted to wind down the program and assure that patients are transitioned out of the trial in a safe and compliant manner. There were no safety concerns observed for rencofilstat in the ASCEND-NASH trial.&quot;</p>


Biotech

General

HEPA

Hepion Pharmaceuticals Says Given The Number Of Enrolled NASH Patients To Date And The Low Probability Of Generating Relevant Efficacy Data To Support A Registrational Trial With Our Current Cash Resources, We Have Opted To Wind Down The Program And Assure That Patients Are Transitioned Out Of The Trial In A Safe And Compliant Manner"

Hepion Pharmaceuticals Shares Resumed Trading

<p>Sen.<strong> Elizabeth Warren</strong> (D-Mass.) voiced her support for a Department of Justice antitrust case against leading technology company <strong>Apple Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), which was <a href="https://www.benzinga.com/news/24/03/37905532/apple-slams-dangerous-doj-lawsuit-tim-cooks-iphone-suggestion-returns-to-haunt-and-potential-google">announced last month.</a></p>
<p>In comments shared on social media, Warren took aim at the smartphone market segment of Apple.</p>
<p><strong>What Happened:</strong> Apple is one of the largest smartphone companies in the world and in 2023 had seven of the top 10 selling smartphones globally <a href="https://www.benzinga.com/news/24/02/37245799/apple-dominates-2023-smartphone-list-with-7-of-top-10-models-why-its-important-for-iphone-growth">according to a report.</a></p>
<p>According to Warren, Apple has a monopoly in the smartphone market and one of the company's key features could be ruining friendships and relationships.</p>
<p>"Green texts on iPhones, they're ruining relationships," Warren <a href="https://twitter.com/SenWarren/status/1781086997014040759">said </a>in a video posted on X.</p>
<p>The green texts refer to the texts that come from non-Apple phones in green bubbles versus the blue bubbles displayed by iPhone users.</p>
<p>"Non iPhone users everywhere are being excluded from group texts."</p>
<p>Warren said that this means some non-Apple smartphone users are not being included in chats about vacation plans, group chats or chats with other sports fans.</p>
<p>"And who's to blame here? Apple."</p>
<p>Warren said that the green vs. blue bubble text icons are just one example of the dirty tactics used by Apple to "keep a stranglehold on the smartphone market."</p>
<p>"Apple has used its monopoly on the smartphone to lock Americans into services and amass billions of dollars in profits."</p>
<p>Warren mentioned that apps that would let Google users use iMessage and get blue texts were <a href="https://www.benzinga.com/news/23/12/36165068/apple-pulls-plug-on-imessage-for-android-app-beeper-mini-its-back-to-green-bubbles-now-for-android-u">blocked by Apple.</a></p>
<p>"It's time to break up Apple's monopoly now."</p>
<p><em>Related Link: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37876155/apple-doj-lawsuit-could-challenge-core-business-model-leading-analyst-predicts-what">Apple DOJ Lawsuit Could Challenge &#8216;Core Business Model&#8217;: Leading Analyst Predicts What&#8217;s Next For Tech Giant</a></em></p>
<p><strong>Why It's Important</strong>: The video shared by Warren was Community Noted on X, with readers providing more context.</p>
<p>"As of Jan 2024, iPhone has a 57% market share, to Android 42% in North America. A monopoly is exclusive control, or no close substitutes," the note reads.</p>
<p>In March, the Department of Justice filed an antitrust suit against Apple, which includes allegations that the company restricts access to iPhone hardware and software features.</p>
<p>A <a href="https://9to5mac.com/2024/04/19/elizabeth-warren-on-green-texts/">report </a>from 9to5Mac indicates that the antitrust lawsuit now encompasses claims from non-iPhone users who feel socially stigmatized and excluded in chats with iPhone users. This issue stems from the ongoing<a href="https://www.benzinga.com/news/23/09/34818276/get-the-message-google-roasts-apple-with-new-mocking-ipager-add-to-end-green-vs-blue-text-bubbles-wa"> blue vs. green bubble text debate.</a></p>
<p><strong>AAPL Price Action</strong>: Apple shares closed at $165.00 on Friday, versus a 52-week trading range of $162.80 to $199.62.</p>
<p><em>Read Next:<a href="https://www.benzinga.com/general/politics/24/04/38305131/elizabeth-warren-says-trump-had-only-2-accomplishments-as-president-huge-difference-between-bide"> Elizabeth Warren Says Trump Had Only 2 Accomplishments As President: &#8216;Huge Difference Between&#8217; Biden, Trump</a></em></p>
<p><em>Photo: Shutterstock</em></p>


Politics

Legal

AAPL

Elizabeth Warren Attacks Apple Smartphone 'Monopoly': 'Green Texts On iPhones, They're Ruining Relationships'

Trading Halt: Halt status updated at 4:55:00 PM ET: Quotation Resumption: News and Resumption Times

Management

AFJK

On April 15, Aimei Health Technology's Juan Fernandez Pascual Tendered His Resignation As CEO, Secretary And A Director; Co Appointed Junheng Xie As CEO, Secretary And A Director

Honda Exec Says Company To Invest 4.2B Reais In Brazil Plant, Focusing On Hybrid-Flex Vehicles

COSM

Cosmos Health Received Nasdaq Notice On Late Filing Of Its Form 10-K; On April 17 Received Notification Letter Stating Co Is No Longer In Compliance With Nasdaq Listing Rule 5250(c)(1); Intends To Resolve Deficiency And Regain Compliance With Nasdaq Listing Rules

BTOG

On Feb 19, Bit Origin Ltd Terminated Employment Of Its CFO, Xia Wang; On April 10, Lucas Wang Resigned As CEO And Chairman Of Board; Current COO, Has Been Appointed CEO, Chairman Of Board And A Director Of Co; Co To Conduct A Search To Replace Xia Wang As Company's CFO

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>ServiceNow</strong>.</p>
<p>Looking at options history for ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) we detected 56 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 35% of the investors opened trades with bullish expectations and 64% with bearish.</p>
<p>From the overall spotted trades, 25 are puts, for a total amount of $1,473,153 and 31, calls, for a total amount of $2,469,435.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $300.0 to $1040.0 for ServiceNow over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for ServiceNow's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of ServiceNow's whale trades within a strike price range from $300.0 to $1040.0 in the last 30 days. </p>
<h3>ServiceNow Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713559550_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$108.8</td>
<td>$106.7</td>
<td>$108.8</td>
<td>$700.00</td>
<td>$598.4K</td>
<td style="text-align: right;">142</td>
<td style="text-align: right;">56</td>
</tr>
<tr>
<td>NOW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$37.0</td>
<td>$31.7</td>
<td>$36.5</td>
<td>$500.00</td>
<td>$310.2K</td>
<td style="text-align: right;">35</td>
<td style="text-align: right;">85</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/10/24</td>
<td>$39.1</td>
<td>$36.7</td>
<td>$39.1</td>
<td>$700.00</td>
<td>$293.2K</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">75</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$32.8</td>
<td>$32.1</td>
<td>$32.1</td>
<td>$720.00</td>
<td>$227.9K</td>
<td style="text-align: right;">75</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$33.0</td>
<td>$31.9</td>
<td>$33.0</td>
<td>$800.00</td>
<td>$132.0K</td>
<td style="text-align: right;">131</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About ServiceNow</h3>
<p>ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.</p>
<h3>Current Position of ServiceNow</h3>
<ul>
<li>Trading volume stands at 1,536,830, with NOW's price down by -2.39%, positioned at $713.91.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 5 days.</li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for ServiceNow, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

This Is What Whales Are Betting On ServiceNow

<p>Financial giants have made a conspicuous bearish move on AstraZeneca. Our analysis of options history for AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) revealed 12 unusual trades.</p>
<p>Delving into the details, we found 16% of traders were bullish, while 83% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $90,336, and 9 were calls, valued at $981,928.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $66.0 and $77.5 for AstraZeneca, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for AstraZeneca's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AstraZeneca's whale activity within a strike price range from $66.0 to $77.5 in the last 30 days. </p>
<h3>AstraZeneca Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713559545_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$1.06</td>
<td>$0.9</td>
<td>$0.9</td>
<td>$67.50</td>
<td>$594.6K</td>
<td>14.1K</td>
<td>8.2K</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$1.65</td>
<td>$1.54</td>
<td>$1.55</td>
<td>$67.00</td>
<td>$69.4K</td>
<td>2.5K</td>
<td>2.3K</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$1.52</td>
<td>$1.51</td>
<td>$1.51</td>
<td>$67.00</td>
<td>$67.6K</td>
<td>2.5K</td>
<td>1.0K</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/19/24</td>
<td>$1.49</td>
<td>$1.25</td>
<td>$1.49</td>
<td>$67.00</td>
<td>$66.7K</td>
<td>2.5K</td>
<td>24</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$1.57</td>
<td>$1.48</td>
<td>$1.49</td>
<td>$67.00</td>
<td>$49.6K</td>
<td>2.5K</td>
<td>920</td>
</tr>
</tbody>
</table>
</p>
<h3>About AstraZeneca</h3>
<p>A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.</p>
<p>Following our analysis of the options activities associated with AstraZeneca, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is AstraZeneca Standing Right Now?</h3>
<ul>
<li>With a trading volume of 4,720,283, the price of AZN is up by 0.28%, reaching $68.55.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 6 days from now.</li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest AstraZeneca options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Looking At AstraZeneca's Recent Unusual Options Activity

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Astera Labs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ALAB, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 9 options trades for <strong>Astera Labs</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 44% bullish and 55%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $55,500, and 8, calls, for a total amount of $413,781.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $35.0 to $100.0 for Astera Labs during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Astera Labs's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Astera Labs's whale trades within a strike price range from $35.0 to $100.0 in the last 30 days. </p>
<h3>Astera Labs Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713559539_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$21.0</td>
<td>$20.0</td>
<td>$21.0</td>
<td>$50.00</td>
<td>$73.5K</td>
<td style="text-align: right;">43</td>
<td style="text-align: right;">39</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$32.7</td>
<td>$30.9</td>
<td>$32.52</td>
<td>$35.00</td>
<td>$65.0K</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$7.7</td>
<td>$7.6</td>
<td>$7.6</td>
<td>$65.00</td>
<td>$63.8K</td>
<td style="text-align: right;">37</td>
<td style="text-align: right;">89</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$6.1</td>
<td>$5.6</td>
<td>$5.9</td>
<td>$65.00</td>
<td>$59.0K</td>
<td style="text-align: right;">37</td>
<td style="text-align: right;">472</td>
</tr>
<tr>
<td>ALAB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$11.1</td>
<td>$10.7</td>
<td>$11.1</td>
<td>$75.00</td>
<td>$55.5K</td>
<td style="text-align: right;">425</td>
<td style="text-align: right;">66</td>
</tr>
</tbody>
</table>
</p>
<h3>About Astera Labs</h3>
<p>Astera Labs Inc is a company that offers an Intelligent Connectivity Platform, comprised of Semiconductor-based, high-speed mixed-signal connectivity products that integrate a matrix of microcontrollers and sensors. COSMOS, their software suite which is embedded in its connectivity products and integrated into their customers' systems. The Company delivers critical connectivity performance, enables flexibility and customization, and supports observability and predictive analytics. This approach addresses the data, network, and memory bottlenecks, scalability, and other infrastructure requirements of hyperscalers and system original equipment manufacturers.</p>
<p>Having examined the options trading patterns of Astera Labs, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Astera Labs</h3>
<ul>
<li>Trading volume stands at 3,996,863, with ALAB's price down by -10.18%, positioned at $63.7.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 14 days.</li>
</ul>
<h3>What Analysts Are Saying About Astera Labs</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $88.0.</p>
<ul>
<li>Reflecting concerns, an analyst from Evercore ISI Group lowers its rating to Outperform with a new price target of $100.</li>
<li>An analyst from Barclays downgraded its action to Overweight with a price target of $85. </li>
<li>Reflecting concerns, an analyst from Roth MKM lowers its rating to Buy with a new price target of $85.</li>
<li>In a cautious move, an analyst from JP Morgan downgraded its rating to Overweight, setting a price target of $85. </li>
<li>Reflecting concerns, an analyst from Needham lowers its rating to Buy with a new price target of $85.</li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Astera Labs, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Decoding Astera Labs's Options Activity: What's the Big Picture?

GILD

LPTX

Leap Therapeutics 13G Filing Shows Gilead Sciences, Inc. Reported A 13.9% Stake In The Co As Of April 10, 2024

Offerings

KZIA

Kazia Therapeutics Ltd Entered Into Purchase Agreement With Alumni Capital LP; Pursuant To Purchase Agreement, May Sell To Alumni Capital Up To $15M Of American Depositary Shares From Time To Time

MNTS

Momentus Inc Receives Nasdaq Deficiency Notification Regarding Delayed Form 10-K

<p>Gulf Resources, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GURE#NASDAQ">GURE</a>) ("Gulf Resources" or the "Company"), a leading manufacturer of bromine, crude salt and specialty chemical products in China, today announced that it received a notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that due to the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the "2023 Form 10-K"), with the Securities and Exchange Commission (the "SEC"), the Company is not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires the timely filing of all required periodic reports with the SEC.<br /><br />&nbsp;</p>
<p>The Notice has no immediate effect on the listing of the Company's common stock on Nasdaq. Under the Nasdaq rules, the Company has 60 calendar days, or until June 17, 2024, to file the 2023 Form 10-K or to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rule. If the Company submits a plan to Nasdaq and Nasdaq accepts the plan, Nasdaq can grant an exception of up to 180 calendar days from the filing's due date, or until October 14, 2024, to regain compliance. If the Company fails to timely regain compliance with Nasdaq Listing Rule 5250(c)(1), the Company's common stock will be subject to delisting from Nasdaq.</p>
<p>The Company continues to work diligently to complete the 2023 Form 10-K and currently intends to file the 2023 Form 10-K by no later than June 10, 2024.</p>
<p>This announcement is made in compliance with the Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a notification of deficiency.</p>


GURE

Gulf Resources Announces Receipt Of Nasdaq Non-Compliance Notice Notifying The Company That Due To The Co's Failure To Timely File Its Annual Report On Form 10-K For The Fiscal Year Ended December 31, 2023

<p>Lifecore Biomedical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>) (the "Company") announced today that, on April 15, 2024, the Company received a notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, as a result of the Company's delay in filing its Quarterly Report on Form 10-Q for the fiscal quarter ended February 25, 2024 (the "Q3 Form 10-Q") and its continued delay in filing its Quarterly Report on Form 10-Q for the quarterly periods ended August 27, 2023 and November 29, 2023 (the "Q1 Form 10-Q" and "Q2 Form 10-Q," respectively, and together with the Q3 Form 10-Q, the "Filings") with the Securities and Exchange Commission (the "SEC"), the Company continues not to be in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"), and that the Nasdaq Hearings Panel would consider the delinquency in the filing of the Q3 Form 10-Q in rendering its determination regarding the Company's continued listing on Nasdaq Global Select Market.<br /><br />&nbsp;</p>
<p>The Notice has no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Global Select Market. As previously disclosed, Nasdaq had previously granted the Company until February 12, 2024 to regain compliance with the Listing Rule, and, on February 13, 2024, the Company received the Staff Delisting Determination notifying the Company that Nasdaq has initiated a process which could result in the delisting of the Company's securities from Nasdaq as a result of the Company not being in compliance with the Listing Rule. The Company appealed the Staff Delisting Determination, and, on April 16, 2024, the Company appeared for the hearing in which the Company requested a further stay of any suspension or delisting action to enable the Company to regain compliance with the Listing Rule. The Nasdaq Hearings Panel has not yet issued its decision, although the Company anticipates that a decision will be forthcoming.</p>
<p>The Company continues to work diligently to complete the Filings and intends to file the Filings as promptly as possible to regain compliance under the Listing Rule. However, there can be no assurance that such periodic reports will be filed before the expiration of any stay granted by Nasdaq, or that the Nasdaq Hearing Panel will grant the Company's request for a further stay of any suspension or delisting action</p>
<p>This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.</p>


LFCR

Lifecore Biomedical, Inc. Receives Notice From Nasdaq Regarding Delayed Quarterly Report For The Fiscal Quarter Ended February 25, 2024 And Its Continued Delay In Filing Its Quarterly Report On Form 10-Q For The Quarterly Periods Ended August 27, 2023 And November 29, 2023

<p>Odyssey Marine Exploration, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>), a global subsea mineral exploration and validation company, reported that on April 17, 2024, Odyssey received a notice from Nasdaq Regulation that Odyssey is not in compliance with Nasdaq Rule 5250(c)(1) because it had not yet filed its Form 10-K for the period ended December 31, 2023 (the "Form 10-K") with the Securities and Exchange Commission (SEC). Odyssey plans to regain compliance with Nasdaq Rule 5250(c)(1) by filing the Form 10-K with the SEC, which it expects to do as soon as practicable.</p>


OMEX

Odyssey Marine Exploration Addresses NASDAQ Compliance Matters; Plans To Regain Compliance With Nasdaq Rule 5250(c)(1) By Filing The Form 10-K With The SEC, Which It Expects To Do As Soon As Practicable

Outlook Therapeutics (OTLK) has provided an announcement. Outlook Therapeutics, Inc. has incentivized its top executives with stock options under i...

Outlook Therapeutics Grants Stock Options to Top Executives

In a report released today, Julian Harrison from BTIG upgraded Outlook Therapeutics (OTLK – Research Report) to a Buy, with a price target of $50.0...

Buy Rating for Outlook Therapeutics: Promising FDA Developments and Strong Financial Position Support $50 Price Target

Outlook Therapeutics Inc (OTLK) has gained Wednesday morning, with the stock gaining 6.45% in pre-market trading to 9.24. OTLK's short-term technical score of 43 indicates that the stock has traded less bullishly over the last month than 57% of stocks on the market. In the Biotechnology industry, which ranks 100 out of 146

Premarket Mover: Outlook Therapeutics Inc (OTLK) Up 6.45%

Outlook Therapeutics shares rise after "buy" rating from BTIG

Outlook Therapeutics shares rise after 'buy' rating from BTIG

Outlook Therapeutics Inc (OTLK) is around the top of the Biotechnology industry according to InvestorsObserver. OTLK received an overall rating of 61, which means that it scores higher than 61 percent of all stocks. Outlook Therapeutics Inc also achieved a score of 71 in the Biotechnology industry, putting it above 71 perc

Should Biotechnology Stock Outlook Therapeutics Inc (OTLK) Be in Your Portfolio Thursday?

Outlook Therapeutics files for $300M mixed securities shelf

Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval

Outlook Therapeutics Inc (OTLK) is around the top of the Healthcare sector according to InvestorsObserver.OTLK received an overall rating of 70, which means that it scores higher than 70% of stocks. Additionally, Outlook Therapeutics Inc scored a 90 in the Healthcare sector, ranking it higher than 90% of stocks in that sec

Should You Add Outlook Therapeutics Inc (OTLK) Stock to Your Portfolio Monday?

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a>. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result. And poor results can happen to anybody, big or small.</p>



<p>Indeed, the prospect of being on the wrong end of a giant killing adds significant risk to market participants. So, as a calculated approach, since you&rsquo;re going to be taking huge risks anyways, you might as well go for ideas with the substantial upside return potential. On that note, below are under-$10 biotech stocks to consider.</p>



<h2>Actinium Pharmaceuticals (ATNM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div><p>Based in New York, <strong>Actinium Pharmaceuticals</strong> (NYSEAMERICAN:<a href="https://investorplace.com/stock-quotes/atnm-stock-quote/"><strong>ATNM</strong></a>) is a clinical-stage biopharmaceutical company <a href="https://finance.yahoo.com/quote/ATNM/profile">developing targeted radiotherapies</a>. Specifically, it delivers cancer-killing radiation to treat patients with high unmet medical needs. Actinium features a product candidate which is in Phase 3 clinical trials for elderly relapsed or refractory acute myeloid leukemia.</p>



<p>Currently, Wall Street analysts rate ATNM a <a href="https://www.tipranks.com/stocks/atnm/forecast">unanimous strong buy</a>. Their average price target stands at $30.50, implying nearly 239% upside potential. Notably, the high-side estimate calls for a price of $50. Among the covering experts, they&rsquo;re anticipating fiscal 2024 loss per share to land at $1.73. Though not profitable, this forecast represents an improvement over last year&rsquo;s loss of $1.83.</p>



<p>At the moment, Actinium is practically a pre-revenue enterprise. If we want to dive into the minutia, it did post sales of $81,000 last year. However, it&rsquo;s not projected to generate any sales this year. However, in fiscal 2025, analysts are looking for sales of $72.82 million. Therefore, it&rsquo;s one of the more promising ideas for under-$10 biotech stocks to consider.</p>



<h2>Outlook Therapeutics (OTLK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/03/eyes-stock-1-300x169.png" alt="Image of a woman with a digital display over her eye."><div>Source: Who is Danny / Shutterstock.com</div></div><p>Headquartered in Iselin, New Jersey, <strong>Outlook Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/otlk-stock-quote/"><strong>OTLK</strong></a>) operates as a clinical-stage biopharmaceutical company. It focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate, <a href="https://ir.oncobiologics.com/news-releases/news-release-details/outlook-therapeuticsr-receives-european-union-positive-chmp#:~:text=ONS%2D5010%2FLYTENAVA%E2%84%A2%20is,AMD%20and%20other%20retinal%20diseases.">ONS-5010 for the treatment of wet age-related macular degeneration</a> and other retina diseases is currently in Phase 3 clinical trials.</p>



<p>Presently, Wall Street rates OTLK a <a href="https://www.tipranks.com/stocks/otlk/forecast">unanimous strong buy</a>. Further, the average price target lands at $40.20, implying 362% growth potential. Moreover, the highest price target hits $60, emphasizing the broad enthusiasm for this biotech firm. For fiscal 2024, experts see the company posting a loss per share of $3.28. Yes, it&rsquo;s in the red but it&rsquo;s an improvement over last year&rsquo;s $4.80 below breakeven.</p>



<p>However, the top line is where things get exciting. Analysts see revenue reaching $240,000, with the high-side estimate hitting $1.43 million. Last year, Outlook did not generate any sales. Even better, forecasts call for fiscal 2025 sales to hit $13.09 million. Thus, it&rsquo;s a compelling idea for under-$10 biotech stocks.</p>



<h2>Recursion Pharmaceuticals (RXRX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/07/rxrx1600-300x169.png" alt="Recursion Pharmaceuticals (RXRX) website displayed on a modern smartphone"><div>Source: Piotr Swat / Shutterstock.com</div></div><p>A clinical-stage biotech firm, <strong>Recursion Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/rxrx-stock-quote/"><strong>RXRX</strong></a>) engages in integrating technological innovations across biology, automation, data science and engineering to industrialize drug discovery. One of its lead product candidates, a therapeutic for treating cerebral cavernous malformation, is currently in Phase 2 clinical trials.</p>



<p>Per analysts, RXRX stock represents a <a href="https://www.tipranks.com/stocks/rxrx/forecast">moderate buy</a>. Further, the average price target lands at $17, implying over 102% upside potential. For the current fiscal year, experts anticipate Recursion to post a loss per share of $1.72. Admittedly, that&rsquo;s worse than last year&rsquo;s red ink of $1.58. That said, the most optimistic assessment calls for a loss of $1.49.</p>



<p>On the top line, the news becomes substantially more favorable. Analysts are looking for sales of $56.16 million,. That would be up 26% from last year&rsquo;s tally of $44.58 million. For fiscal 2025, they&rsquo;re looking for revenue of $88.43 million, up 57.5% against projected 2024 sales. If you like to speculate, RXRX belongs on your radar of under-$10 biotech stocks to buy.</p>



<h2>Ocular Therapeutix (OCUL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/12/eye-1600-300x169.jpg" alt="A close-up of someone's eye"><div>Source: Shutterstock</div></div><p>Headquartered in Bedford, Massachusetts, <strong>Ocular Therapeutix</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/ocul-stock-quote/"><strong>OCUL</strong></a>) is a biopharma company focused on the formulation, development and commercialization of therapies for diseases and conditions of the eye. It uses a bioresorbable hydrogel-based formulation technology. It&rsquo;s developing an <a href="https://www.ophthalmologytimes.com/view/ocular-therapeutix-inc-screens-first-3-patients-in-phase-3-sol-1-trial">axitinib intravitreal implant that is in Phase 3 trials</a> for the treatment of wet age-related macular degeneration.</p>



<p>Per Wall Street analysts, OCUL rates as a <a href="https://www.tipranks.com/stocks/ocul/forecast">consensus strong buy</a>. On average, the price target stands at $16.33, implying over 104% upside potential. Further, the most optimistic target calls for a price of $24. Covering experts see fiscal 2024&rsquo;s loss per share coming in at 83 cents. While not a profitable enterprise, this figure would represent a conspicuous improvement over last year&rsquo;s loss of $1.02.</p>



<p>On the top line, analysts anticipate revenue to hit $68.34 million. If so, we&rsquo;re talking about year-over-year growth of 16.9% from last year&rsquo;s haul of $58.44 million. For fiscal 2025, they&rsquo;re looking for sales of $85.9 million. Even better, the highest target seeks a top-line print of $116 million. Overall, it&rsquo;s a compelling take for under-$10 biotech stocks.</p>



<h2>Marinus (MRNS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div><p>Based in Radnor, Pennsylvania, <strong>Marinus</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrns-stock-quote/"><strong>MRNS</strong></a>) is a pharmaceutical company focusing on the development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. Its <a href="https://ir.marinuspharma.com/news/news-details/2024/Marinus-Pharmaceuticals-Reports-Preliminary-Fourth-Quarter-and-Full-Year-2023-ZTALMY-Net-Product-Revenue-and-Provides-Business-Update/default.aspx">main product is Ztalmy</a>, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations.</p>



<p>Presently, covering experts rate MRNS stock as a <a href="https://www.tipranks.com/stocks/mrns/forecast#">consensus strong buy</a>. The average price target lands at $19.78, implying 163% growth potential. Also, the highest target calls for a price per share of $28. For the current fiscal year, analysts are looking for a loss per share of $2.36. While the bottom line is printed in red ink, the projected figure would be an improvement over last year&rsquo;s loss of $2.63 per share.</p>



<p>On the top line, analysts are looking for revenue of $40.53 million. That would imply YOY growth of nearly 31% from last year&rsquo;s haul of $30.99 million. Further, the most optimistic target seeks a sales print of $54.3 million. For fiscal 2025, revenue could rise to $66.62 million. Based on the growth potential, MRNS is one of the under-$10 biotech stocks to consider.</p>



<h2>Fulcrum Therapeutics (FULC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/medical-biotech-stocks1600-300x169.png" alt="Healthcare business graph data and growth, Medical examination and doctor analyzing medical report network connection on tablet screen. VANI stock"><div>Source: PopTika / Shutterstock.com</div></div><p>Calling Cambridge, Massachusetts home, <strong>Fulcrum Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/fulc-stock-quote/"><strong>FULC</strong></a>) is a clinical-stage biopharma focusing on the development of products for improving the lives of patients suffering from genetically defined diseases. In particular, it seeks to address conditions with high unmet medical needs. It features a small-molecule-based candidate that&rsquo;s in Phase 3 trials for the treatment of muscular dystrophy.</p>



<p>Presently, Wall Street analysts rate FULC a <a href="https://www.tipranks.com/stocks/fulc/forecast">consensus strong buy</a> with a $13.29 average price target. That implies over 77% upside potential. Further, the most optimistic forecast calls for a price per share of $17. For fiscal 2024, covering experts are anticipating a loss per share of $1.75. Admittedly, that&rsquo;s an expansion of last year&rsquo;s red ink of $1.59 per share.</p>



<p>It also doesn&rsquo;t immediately get better on the top line, with analysts projecting sales of $1.92 million. Conspicuously, that&rsquo;s 31.6% off the pace of last year&rsquo;s tally of $2.81 million. Still, the focal point is on fiscal 2025&rsquo;s projected sales of $13.34 million. Further, the high-side estimate lands at $42.88 million. Therefore, for the patient speculator, FULC could be one of the under-$10 biotech stocks to buy.</p>



<h2>CorMedix (CRMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715-300x169.png" alt="Biochemical/biotech research scientist team working with microscope"><div>Source: Mongkolchon Akesin / Shutterstock.com</div></div><p>Headquartered in Berkeley Heights, New Jersey, <strong>CorMedix</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/crmd-stock-quote/"><strong>CRMD</strong></a>) is a biopharma firm focusing on the development and commercialization of therapeutic products in the prevention and treatment of infectious and inflammatory diseases. Its lead product candidate is <a href="https://cormedix.com/cormedix-inc-announces-commercial-and-operational-updates/">DefenCath, an antimicrobial catheter lock solution</a> to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.</p>



<p>Although it&rsquo;s one of the riskiest under-$10 biotech stocks, it also enjoys plenty of love on the Street. Analysts rate shares a unanimous strong buy with a $12.67 price target. That implies upside potential of just under 117%. Also, the high-side target hits $19.</p>



<p>For fiscal 2024, experts are looking at a loss per share of 74 cents. That&rsquo;s still in the red but an improvement over last year&rsquo;s loss of 91 cents. On the top line, they&rsquo;re seeking $25.16 million. Last year, the company generated no revenue. Finally, for fiscal 2025, experts are seeking sales of $81.93 million, implying 225.6% YOY growth from projected 2024 revenue.</p>



<p><em>On the date of publication, Josh Enomoto</em><em> did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;</em><em>The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em><em></em></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/04/biotech-on-a-budget-7-stocks-under-10-with-huge-potential/">Biotech on a Budget: 7 Stocks Under $10 With Huge Potential</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Biotech on a Budget: 7 Stocks Under $10 With Huge Potential

ATNM

CRMD

FULC

MRNS

NVSEF

OCUL

REGN

RHHBF

RHHBY

RHHVF

RXRX

Press Releases

Outlook Therapeutics Investors: Company Investigated by the Portnoy Law Firm

Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010

Health Care

Outlook Therapeutics® Doses First Subject in NORSE EIGHT

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update

Kaskela Law LLC Announces Shareholder Investigation of Outlook Therapeutics, Inc. (OTLK) and Encourages Investors to Contact the Firm

Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split

Opinion

Thinking about buying stock in Mind Medicine, Ocean Biomedical, Archer Aviation, Outlook Therapeutics, or Cardiff Oncology?

Financing

Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million

Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million

ACHR

CRDF

MNMD

Abeona Therapeutics

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adicet Bio

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

Atossa Therapeutics

bluebird bio

Cellectis S.A. - American Depositary Shares

Cellectis

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Cardiff Oncology

Elevation Oncology

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Generation Bio

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Genfit

Gossamer Bio

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Inventiva S.A. - American Depository Shares

Inventiva

Kodiak Sciences

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Poseida Therapeutics, Inc. - Common Stock

Poseida Therapeutics

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

X4 Pharmaceuticals

YS Biopharma Co

Zura Bio Limited - Class A Ordinary shares

Zura Bio

BTIG

HC Wainwright & Co.